Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022.
Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.
The Galea platform is designed to offer the opportunity to create your own tournaments and to share...
LILM is a website that allows you to order custom furniture directly from artisans. LILM finds you d...
The Franklin ice creams are originating from Binche. They are artisanal ice creams, without added su...
Utopix is the first Belgian platform specialized in providing companies and agencies with profession...
Eventer is a free solution for anyone who wants to easily collect all the memories of an event and h...
WooClap is a tool that allows you to interactively engage your audience or learners during a present...
Apaxen is a biotechnology company developing therapeutic anti-inflammatory drugs for the treatment o...
Recruiting IT developers has never been so complicated due to the impact of digital transformation o...
BeCentral is a digital campus located in the heart of Brussels
Foot 24/7 has developed an application entirely dedicated to soccer players that allows you to creat...